Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension
The ALEPH trial aims to generate high-quality evidence regarding the efficacy and safety of ambrisentan monotherapy in early-stage, low-risk PAH. This study may provide valuable insight into early therapeutic intervention for patients with mild hemodynamic disorder. (Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension [ALEPH]; NCT06987097).
Authors
- Jun Luo (ORCID: https://orcid.org/0000-0003-3339-5566)
- Wande Yu (ORCID: https://orcid.org/0000-0002-3544-3640)
- Xiaofeng Liu (ORCID: https://orcid.org/0000-0002-0447-5658)
- Guan-Wen Ding
- Dujiang Xie
- Zhenwen Yang
- S L Chen
- Hang Zhang
- Fen-Ling Fan
- Wei Li
- Jun-Yan Kan
- Xiao-Juan Zhang
Institutions
- Emory University (US)
- Tianjin Medical University General Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- JACC Asia
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jacasi.2025.12.014
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00